The Comparison of Silver Serum Levels and Acute Toxic Effects of Nano-Silver on Histopathology of Organs (Lungs, Liver, Kidney, Brain) in Two Types of AgiCoat and Acticoat Dressings on Second-Degree Deep Burn in Rat

Jafarnejad, B; Karimi, H; Hafezi, F; Fatemi, MJ; Zare Mehrjardi, A; Saberi, M

The Comparison of Silver Serum Levels and Acute Toxic Effects of Nano-Silver on Histopathology of Organs (Lungs, Liver, Kidney, Brain) in Two Types of AgiCoat and Acticoat Dressings on Second-Degree Deep Burn in Rat

Document Type : Original Article

Authors

B Jafarnejad ¹

H Karimi ²

F Hafezi ³

MJ Fatemi ⁴

A Zare Mehrjardi ⁵

M Saberi ⁶

¹ Assistant Professor, Department of Reconstructive and Plastic Surgery, Iran University of Medical Sciences, Hazrat Fatemeh Hospital (SA)

² Professor of Plastic & Reconstructive Surgery, Burn Research Center, Iran University of Medical Sciences, Hazrate Fateme Hospital, Tehran, Iran

³ Professor, Department of Reconstructive and Plastic Surgery, Burn Research Center, Iran University of Medical Sciences, Hazrat Fatemeh Hospital (S)

⁴ Professor, Department of Reconstructive and Plastic Surgery, Burn Research Center, Iran University of Medical Sciences, Hazrat Fatemeh Hospital (SA)

⁵ Associate Professor, Department of Pathology, Iran University of Medical Sciences

⁶ Assistant Professor, Department of Social Medicine, Baqiyatallah University of Medical Sciences, Medicine, Quran and Hadith Research Center

Abstract

Introduction & Objective: Antimicrobial resistance is a major problem that imposes high costs on burn patients. Therefore, selection of newer methods in order to deal with complications and side effects such as infection or delay in wound healing is needed. The aim of this study was to compare Silver serum levels and acute toxic effects of Nano-silver on histopathology of organs (lungs, liver, kidney, brain) in two types of AgiCoat and Acticoat dressings on second-degree deep burn in rat. Materials & Methods: This is an experimental study conducted at animal laboratory of Hazrat Fatima Hospital in 1394. We divided 24 Sprague-Dawley male rats weighing 300 to 350 randomly into two groups. After burning dorsal skin of rats in the first and the second group, their dressings were changed every three days with AgiCoat and Acticoat respectively. After 14 days, we sent blood samples taken from heart, liver, kidneys, lungs and brain and a sample from dorsal skin of the rat to the lab in order to do histopathological examinations. Then the data were analyzed using by SPSS software, version 20 and one-sample, independent-sample test and ANOVA. Results: The results of this study showed that the level of silver serum per Microgram per Liter in the Agicoat group was 17.644±20.371 and in the Acticoat group was 21.800±12.199 and was a significant difference (AgiCoat = 0.017) (Acticoat = P < 0.001). However, in terms of silver serum levels in two groups, there was no significant difference (P = 0.551). Examination of The relationship between the level of silver serum and histopathological changes in liver showed that hepatotoxicity of Agicoat compared to Acticoat was higher and the different was significant (P = 0.002). Conclusions: These dressings can cause toxicity and liver pathology. Although it does not seem only dressings cause this problem. Other factors such as weight, host resistance, immune system and etc should be considered important. Since the increase in blood silver would lead to an excessive injury, we recommend further studies on these dressings and similar products.

Keywords

Toxicity

Nano-Silver

Second-Degree Deep Burn

1. Jemec GB, Gniadecka M, Ulrich J. Ultrasound in dermatology. Part I. High frequency ultrasound. European journal of dermatology: EJD. 2000 Aug; 10(6): 492-7.

2. Singer AJ, Clark RA. Cutaneous wound healing. New England journal of medicine. 1999 Sep 2; 341(10): 738-46.

3. Leaper DJ. Silver dressings: their role in wound management. International wound journal. 2006 Dec 1; 3(4): 282-94.

4. Wright JB, Lam K, Hansen D, Burrell RE. Efficacy of topical silver against fungal burn wound pathogens. American journal of infection control. 1999 Aug 31; 27(4): 344-50.

5. Logsetty S, Heimbach DM. Modern techniques for wound coverage of the thermally injured upper extremity. Hand clinics. 2000 May; 16(2): 205-14.

6. Fraser JF, Bodman J, Sturgess R, Faoagali J, Kimble RM. An in vitro study of the anti-microbial efficacy of a 1% silver sulphadiazine and 0.2% chlorhexidine digluconate cream, 1% silver sulphadiazine cream and a silver coated dressing. Burns. 2004 Feb 29; 30(1): 35-41.

7. O’Neill MA, Vine GJ, Beezer AE, Bishop AH, Hadgraft J, Labetoulle C, Walker M, Bowler PG. Antimicrobial properties of silver-containing wound dressings: a microcalorimetric study. International journal of pharmaceutics. 2003 Sep 16; 263(1): 61-8.

8. Boateng JS, Matthews KH, Stevens HN, Eccleston GM. Wound healing dressings and drug delivery systems: a review. Journal of pharmaceutical sciences. 2008 Aug 1; 97(8): 2892-923.

9. Atiyeh BS, Hayek SN, Gunn SW. New technologies for burn wound closure and healing-review of the literature. Burns. 2005 Dec 31; 31(8): 944-56.

10. Klasen HJ. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns. 2000 Mar 31; 26(2): 131-8.

11. Kim JS, Kuk E, Yu KN, Kim JH, Park SJ, Lee HJ, Kim SH, Park YK, Park YH, Hwang CY, Kim YK. Antimicrobial effects of silver nanoparticles. Nanomedicine: Nanotechnology, Biology and Medicine. 2007 Mar 31; 3(1): 95-101.

12. Ung T, Liz-Marzán LM, Mulvaney P. Controlled method for silica coating of silver colloids. Influence of coating on the rate of chemical reactions. Langmuir. 1998 Jul 7; 14(14): 3740-8.

13. Brett DW. A discussion of silver as an antimicrobial agent: alleviating the confusion. Ostomy/wound management. 2006 Jan; 52(1): 34-41.

14. Vlachou E, Chipp E, Shale E, Wilson YT, Papini R, Moiemen NS. The safety of nanocrystalline silver dressings on burns: a study of systemic silver absorption. Burns. 2007 Dec 31; 33(8): 979-85.

15. White JM, Powell AM, Brady K, Russell-Jones R. Severe generalized argyria secondary to ingestion of colloidal silver protein. Clinical and experimental dermatology. 2003 May 1; 28(3): 254-6.

16. Hori K, Martin TG, Rainey P, Robertson WO. Believe it or not--silver still poisons! Veterinary and Human Toxicology. 2002 Oct; 44(5): 291-2.

17. Tsuji JS, Maynard AD, Howard PC, James JT, Lam CW, Warheit DB, Santamaria AB. Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles. Toxicological sciences. 2006 Jan 1; 89(1): 42-50.

18. Warheit DB, Borm PJ, Hennes C, Lademann J. Testing strategies to establish the safety of nanomaterials: conclusions of an ECETOC workshop. Inhalation toxicology. 2007 Jan 1; 19(8): 631-43.

19. Crosera M, Bovenzi M, Maina G, Adami G, Zanette C, Florio C, Larese FF. Nanoparticle dermal absorption and toxicity: a review of the literature. International archives of occupational and environmental health. 2009 Oct 1; 82(9): 1043-55.

20. Paddle-Ledinek JE, Nasa Z, Cleland HJ. Effect of different wound dressings on cell viability and proliferation. Plastic and reconstructive surgery. 2006 Jun 1; 117(7S): 110S-8S.

21. Lam PK, Chan ES, Ho WS, Liew CT. In vitro cytotoxicity testing of a nanocrystalline silver dressing (Acticoat) on cultured keratinocytes. British journal of biomedical science. 2004 Jul 1; 61(3): 125.

22. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? Journal of pharmaceutical sciences. 2010 Jan 1; 99(1): 21-50.

23. Chen X, Schluesener HJ. Nanosilver: a nanoproduct in medical application. Toxicology letters. 2008 Jan 4; 176(1): 1-2.

24. Navarro E, Piccapietra F, Wagner B, Marconi F, Kaegi R, Odzak N, Sigg L, Behra R. Toxicity of silver nanoparticles to Chlamydomonas reinhardtii. Environmental science & technology. 2008 Oct 1; 42(23): 8959-64.

25. Blaser SA, Scheringer M, MacLeod M, Hungerbühler K. Estimation of cumulative aquatic exposure and risk due to silver: contribution of
nano-functionalized plastics and textiles. Science of the total environment. 2008 Feb 15; 390(2): 396-409.

26. Chang AL, Khosravi V, Egbert B. A case of argyria after colloidal silver ingestion. Journal of cutaneous pathology. 2006 Dec 1; 33(12): 809-11.

27. Burd A, Kwok CH, Hung SC, Chan HS, Gu H, Lam WK, Huang L. A comparative study of the cytotoxicity of silver-based dressings in monolayer cell, tissue explant, and animal models. Wound repair and regeneration. 2007 Jan 1; 15(1): 94-104.

28. Poon VK, Burd A. In vitro cytotoxity of silver: implication for clinical wound care. Burns. 2004 Mar 31; 30(2): 140-7.

29. Vlachou E, Chipp E, Shale E, Wilson YT, Papini R, Moiemen NS. The safety of nanocrystalline silver dressings on burns: a study of systemic silver absorption. Burns. 2007 Dec 31; 33(8): 979-85.

30. Cuttle L, Naidu S, Mill J, Hoskins W, Das K, Kimble RM. A retrospective cohort study of Acticoat™ versus Silvazine™ in a paediatric population. Burns. 2007 Sep 30; 33(6): 701-7.

31. Stebounova LV, Adamcakova-Dodd A, Kim JS, Park H, O'Shaughnessy PT, Grassian VH, Thorne PS. Nanosilver induces minimal lung toxicity or inflammation in a subacute murine inhalation model. Part Fibre Toxicol 2011; 8(1): 5.

32. Hollinger MA. Toxicological aspects of topical silver pharmaceuticals. Crit Rev Toxicol 1996; 26(3): 255-60.

33. Tang J, Xi T. Status of biological evaluation on silver nanoparticles. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi 2008; 25(4): 958-61.

34. Kim YS, Kim JS, Cho HS, Rha DS, Kim JM, Park JD, et al. Twenty eight-day oral toxicity, genotoxicity, and gender-related tissue distribution of silver nanoparticles in Sprague-Dawley rats. Inhal Toxicol 2008; 20(6): 575-83.

35. Kim YS, Song MY, Park JD, Song KS, Ryu HR, Chung YH, et al. Subchronic oral toxicity of silver nanoparticles. Part Fibre Toxicol 2010; 7(1): 20.

36. Maneewattanapinyo P, Banlunara W, Thammacharoen C, Ekgasit S, Kaewamatawong T. An evaluation of acute toxicity of colloidal silver nanoparticles. J Vet Med Sci 2011; 73(11): 1417-23.

37. Trop M, Novak M, Rodl S, Hellbom B, Kroell W, Goessler W. Silver coated dressing Acticoat caused raised liver enzymes and argyria-like symptoms in burn patient. J Trauma 2006; 60(3): 648-52.

38. Pronk M, Wijnhoven S, Bleeker E, Heugens E, Peijnenburg W, Luttik R, et al. Nanomaterials under REACH. Nanosilver as a case study, RIVM rapport 2009.

39. Park E-J, Bae E, Yi J, et al. Repeated-dose toxicity and inflammatory responses in mice by oral administration of silver nanoparticles. Environ Toxicol Pharmacol 2010; 30: 162-8.

40. Bidgoli SA, Mahdavi M, Rezayat SM, Korani M, Amani A, Ziarati P. Toxicity assessment of nanosilver wound dressing in Wistar rat. Acta Medica Iranica. 2013 Apr 1; 51(4): 203.

41. Korani M, Rezayat SM, Gilani K, Bidgoli SA, Adeli S. Acute and subchronic dermal toxicity of nanosilver in guinea pig. Int J Nanomedicine. 2011 Jan 1; 6(1): 855-62.

42. Hafezi F, Rad HE, Naghibzadeh B, Nouhi A, Naghibzadeh G. Actinidia deliciosa (kiwifruit), a new drug for enzymatic debridement of acute burn wounds. Burns. 2010 May 31; 36(3): 352-5.